Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00462579 · ClinicalTrials.gov registry record
Risk Factors for Carbapenem-resistant Acinetobacter Baumannii
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 100
- Enrollment target
NCT00462579: Completed study, sponsored by University of Pittsburgh.
NCT00462579 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00462579 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
It has been demonstrated that panresistant strains of Acinetobacter species may be selected by antibiotic use \[4\], may be transmitted from person to person \[5\], and may be passed via environmental contamination \[6\]. Surveillance for panresistant Acinetobacter species should be a priority, given the lack of antibiotic options for the treatment of these infections. There are currently no data on the antibiotic susceptibility of Acinetobacter species or on the rates of panresistant organisms. The elucidation of potential risk factors for resistant strains of Acinetobacter is therefore an important task, and the use of alternative antibiotics should be considered in ICUs where these strains are endemic.
Primary Outcome
health status
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2007-04 |
| Est. Completion | 2017-06 |
What the finished NCT00462579 record still lists
NCT00462579 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00462579 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00462579 about?
NCT00462579 is a clinical study titled "Risk Factors for Carbapenem-resistant Acinetobacter Baumannii". It has been demonstrated that panresistant strains of Acinetobacter species may be selected by antibiotic use \[4\], may be transmitted from person to person \[5\], and may be passed via environmental contamination \[6\]. Surveillance for panresistant Acinetobacter species should be a priority, give...
What is the current status of trial NCT00462579?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2007-04. Estimated completion is 2017-06.
Who is sponsoring clinical trial NCT00462579?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia